Daily High‑Dose Mosnodenvir Significantly Lowers DENV‑3 Viremia in a Human Challenge — Proof‑of‑Concept with Early Resistance Signals
Posted inInfectious Diseases news Public Health

Daily High‑Dose Mosnodenvir Significantly Lowers DENV‑3 Viremia in a Human Challenge — Proof‑of‑Concept with Early Resistance Signals

In a phase 2a human challenge, high‑dose daily mosnodenvir substantially reduced DENV‑3 RNA burden versus placebo without serious adverse events, but treatment‑associated NS4B viral mutations emerged, highlighting efficacy and resistance concerns that require larger field studies.
Engasertib Shows Promise for Recurrent Epistaxis in HHT: Proof‑of‑Concept Trial Demonstrates Reduced Bleeding with Acceptable Short‑Term Safety
Posted inHematology-Oncology news Otorhinolaryngology

Engasertib Shows Promise for Recurrent Epistaxis in HHT: Proof‑of‑Concept Trial Demonstrates Reduced Bleeding with Acceptable Short‑Term Safety

In a randomized, double‑blind, placebo‑controlled proof‑of‑concept trial, oral engasertib reduced epistaxis frequency and duration in hereditary hemorrhagic telangiectasia (HHT) with a safety profile similar to placebo except for reversible rash and occasional hyperglycemia.
Ropeginterferon alfa-2b Superior to Anagrelide as Second-line Therapy in Hydroxyurea‑Intolerant or ‑Refractory Essential Thrombocythaemia: SURPASS‑ET Phase 3 Results
Posted inHematology-Oncology news

Ropeginterferon alfa-2b Superior to Anagrelide as Second-line Therapy in Hydroxyurea‑Intolerant or ‑Refractory Essential Thrombocythaemia: SURPASS‑ET Phase 3 Results

SURPASS‑ET, a phase 3 randomized trial, showed ropeginterferon alfa‑2b achieved durable ELN responses in 43% of hydroxyurea‑intolerant/refractory ET patients with leukocytosis versus 6% with anagrelide, with a favorable safety profile and fewer serious adverse events.
Combining Food Biodiversity, Less Processing, and the EAT‑Lancet Diet Improves Nutrient Adequacy and Lowers Environmental Impact: Insights from 368,733 EPIC Participants
Posted inFamily Medicine & Nutrition news Public Health

Combining Food Biodiversity, Less Processing, and the EAT‑Lancet Diet Improves Nutrient Adequacy and Lowers Environmental Impact: Insights from 368,733 EPIC Participants

Multi-objective optimization in the EPIC cohort shows that modest gains in adherence to the EAT‑Lancet diet, increased plant species richness, and substitution of ultra‑processed foods with minimally processed foods can raise nutrient adequacy and reduce greenhouse gas emissions and land use.